In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
Asembia AXS25: Navigating the Evolving Landscape of GLP-1 Medications
Davis discussed the transition from obesity-specific opt-in benefits to more standard coverage. She expects that payers will need to handle a wider range of...